Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Portfolio Pulse from Jelena Martinovic
Enveric Biosciences (NASDAQ:ENVB) has presented promising preclinical research on its non-hallucinogenic psychedelic compound, EB-003, for treating anxiety and depression. The company plans to file an IND application by Q3 2025 and start clinical trials by the end of 2025.
September 25, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has shown promising preclinical results for its non-hallucinogenic psychedelic compound, EB-003, aimed at treating anxiety and depression. The company plans to file an IND application by Q3 2025 and start clinical trials by the end of 2025.
The positive preclinical results for EB-003, a non-hallucinogenic psychedelic compound, suggest potential future success in treating anxiety and depression. The planned IND filing and clinical trials indicate a clear path forward, likely boosting investor confidence and positively impacting ENVB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100